Jim the Meadowman
27.6K posts
@ragabonz
Just a Dad with a Meadow
Check on your people in prison these holidays if you got any. Just a couple more years and my bro gets out. Six years pass in a heartbeat.
@AyoCaesar You’re the retards that want to give 16 year olds the right to vote, are they adults or not?
The CIA CLASSIFIED a 1950s study showing anti-parasitics disrupt cancer growth—and kept it BURIED for over HALF A CENTURY. Millions of cancer victims have paid the price as this vital line of research was set back DECADES.
Mel Gibson: "I have 3 friends. All 3 of them had stage 4 cancer…and all 3 of them…don't have cancer right now at all…" Joe Rogan: "What did they take…? Ivermectin and Fenbendazole…" Mel Gibson nods in agreement.
🔥Dr. John Campbell SHOCKED after reading our ivermectin cancer study: “We could be CURING, potentially … your wife’s cancer, your husband’s cancer, your mother’s cancer, your father’s cancer, your son’s cancer, your daughter’s cancer, with ivermectin and mebendazole.”
🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️ We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology. This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day. The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery. At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]): ✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%) ✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%) ✅ 36.1% reported stable disease (95% CI: 28.1–44.9%) Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months. The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events. Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach. Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies. Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary. This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes. The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
"Today is another promise made, promise kept day... The Acting Attorney General this morning signed an order that moves into Schedule III medical marijuana products that are FDA approved or that are state licensed. This is a giant move forward to implement your promise."
Father and Son Scientists killed 14th and 15th.
St George’s flag stands for unity over hatred and decency over division. Those are the values I will always fight for. Some try to hijack our flag to spread hate, I reject their plastic patriotism. mirror.co.uk/news/politics/…
If attraction isn’t a choice, then it isn’t a choice for men either. Yet men’s preferences for younger women get morally policed far more than some women’s preference for “bad boys”. The latter may be more harmful to women, and to society in terms of incentive structure.
Cocaine, cannabis and prescription drugs sold in UK High Street mini-marts, BBC secret filming reveals bbc.in/42nvhT0
420: THE GLOBAL LANDSCAPE OF CANNABIS CONSUMPTION
